We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

10 hedge funds and large institutions have $5.92M invested in Traws Pharma in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

67% more capital invested

Capital invested by funds: $3.53M → $5.92M (+$2.38M)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

11% more funds holding

Funds holding: 9 → 10 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0.01% (+0%)

Holders
10
Holders Change
+1
Holders Change %
+11.11%
% of All Funds
0.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
5
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$2.79M
2
AC
Armistice Capital
New York
+$1.71M
3
TCP
Tyndall Capital Partners
New York
+$1.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$236K
5
Renaissance Technologies
Renaissance Technologies
New York
+$50K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$207K
2
VF
Virtu Financial
New York
-$19K
3
Citadel Advisors
Citadel Advisors
Florida
-$17K
4
Macquarie Group
Macquarie Group
Australia
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
6CM
1
683 Capital Management
New York
$2.23M +$2.79M +391 +471%
TCP
2
Tyndall Capital Partners
New York
$1.75M +$1.4M +196 +111%
AC
3
Armistice Capital
New York
$1.13M +$1.71M +240 New
SM
4
Sabby Management
Florida
$334K -$207K -29 -29%
Vanguard Group
5
Vanguard Group
Pennsylvania
$287K +$236K +33 +118%
Renaissance Technologies
6
Renaissance Technologies
New York
$123K +$50K +7 +37%
PAM
7
Panagora Asset Management
Massachusetts
$33K +$7.14K +1 +17%
Northern Trust
8
Northern Trust
Illinois
$16K +$21.4K +3 New
Millennium Management
9
Millennium Management
New York
$12K +$21.4K +3 New
Morgan Stanley
10
Morgan Stanley
New York
$8K +$14.3K +2 New
UBS Group
11
UBS Group
Switzerland
$2K – – –
HFM
12
Hartford Financial Management
Connecticut
$1K – – –
LTFS
13
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Citadel Advisors
14
Citadel Advisors
Florida
– -$17K -2 Closed
VF
15
Virtu Financial
New York
– -$19K -2 Closed
Macquarie Group
16
Macquarie Group
Australia
– -$8K -1 Closed

TRAW Hedge Fund Activity: Q1 2018 in Review

10 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2018, worth a combined $5.92M — up 67% from $3.53M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TRAW positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $2.79M. The largest seller was Sabby Management, cutting an estimated $207K.

  • 10 institutional investors held Traws Pharma (TRAW) as of Q1 2018, up from 9 in Q4 2017.
  • Funds reported $5.92M of Traws Pharma stock for Q1 2018, up 67% quarter-over-quarter.
  • 4 funds opened new Traws Pharma positions in Q1 2018 and 3 closed out, a net change of +1 holder.
  • The largest Traws Pharma buyer in Q1 2018 was 683 Capital Management, an estimated $2.79M added.
  • The largest Traws Pharma seller in Q1 2018 was Sabby Management, an estimated $207K sold.

Based on aggregated 13F filings for Q1 2018.